The time-course of protection of the RTS,S vaccine against malaria infections and clinical disease

BACKGROUND: Recent publications have reported follow-up of the RTS,S/AS01 malaria vaccine candidate Phase III trials at 11 African sites for 32 months (or longer). This includes site- and time-specific estimates of incidence and efficacy against clinical disease with four different vaccination sched...

Descripción completa

Detalles Bibliográficos
Autores principales: Penny, Melissa A., Pemberton-Ross, Peter, Smith, Thomas A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4634589/
https://www.ncbi.nlm.nih.gov/pubmed/26537608
http://dx.doi.org/10.1186/s12936-015-0969-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4634589/
https://www.ncbi.nlm.nih.gov/pubmed/26537608
http://dx.doi.org/10.1186/s12936-015-0969-8

Ejemplares similares